Navigation Links
Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
Date:12/21/2011

GREENWOOD VILLAGE, Colo., Dec. 21, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE)("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), announced today that it has entered into definitive agreements with accredited investors to sell an aggregate approximately 2,220,255 of shares of its common stock, par value $0.0001 per share (the "Shares"), at a price per share of $4.25 in a registered direct offering for gross proceeds of approximately $9.436 million, before deducting placement agents' fees and estimated offering expenses.

The Shares are being offered directly by Ampio pursuant to an effective shelf registration statement previously filed with, and declared effective by the Securities and Exchange Commission on October 28, 2011. The Company anticipates that the net proceeds from the offering will be used for general corporate purposes and working capital. The closing of this offering is expected to occur on or about December 27, 2011, subject to the satisfaction of customary closing conditions.

Fordham Financial Management, Inc. and Summer Street Research Partners served as co- lead placement agents and Emerging Growth Equities, Ltd. served as the co-placement agent for the offering. When available, copies of the preliminary prospectus supplement, the prospectus supplement and the accompanying base prospectus relating to the offering may be obtained from the Securities and Exchange Commission website at http://www.sec.gov or Fordham Financial Management, Inc., 14 Wall Street, New York, New York 10005.

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration of qualifica
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ampio Responds to Recent Publications by Anonymous Short Sellers
2. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
3. FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure
4. Ampio Pharmaceuticals Awarded European Patent that Strengthens Intellectual Property Protection for its key drug Ampion™
5. Ampio Pharmaceuticals Announces Agreement to Acquire Key Drug Delivery Technology
6. Ampio Pharmaceuticals Expands Patent Portfolio of Drugs for Treating Inflammatory Diseases
7. Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation
8. Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Management Team and Corporate Office Relocation
9. Ampio Pharmaceuticals Announces a Proof of Concept Trial of Danazol in the Treatment of Allergic Rhinitis Supports Mechanism of Action of Optina™
10. Ampio Pharmaceuticals Receives Notice of Allowance of its Two Patent Applications on the Combination of Zertane™ with Erectile Dysfunction Drugs in Canada
11. Ampio Announces Positive Results From 12-Week Open Label Extension Study of Zertane™ in Patients With Premature Ejaculation.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 2015  Mytrus, a technology and services company revolutionizing clinical trials, ... consent has received approval for use by ... the first time e-Consent technology will be used in ... Mytrus was also the first electronic informed ... by the U.S. Food and Drug Administration in 2011. ...
(Date:8/27/2015)... NEW YORK , Aug. 27, 2015   ... cord tissue , and placenta tissue ... innovative cord blood banking e-commerce website. This new website ... than ever with an interactive shopping cart and checkout ... "Most cord blood banking websites make this ...
(Date:8/27/2015)... , August 27, 2015 ... Persistence Market Research titled "Global Market Study on ... Growth by 2021", the urinary catheters market is expected to ... of 2015. It is anticipated to expand at ... reach US$1,755.0 Mn by 2021. View ...
Breaking Medicine Technology:Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 5Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 6Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 7Cord Blood Bank Revolutionizes Process of Online Cord Blood Banking 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 3Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 4
... , SAN DIEGO, Oct. 26 Horizon Therapeutics, ... an analysis from two pivotal Phase 3 trials ... HZT-501, a combination of ibuprofen with high-dose famotidine. ... risk factors for the development of non-steroidal anti-inflammatory ...
... Volcano Corporation (Nasdaq: VOLC ), a leader in ... and treatment of coronary and peripheral artery disease, today announced ... quarter and first nine months of fiscal 2009 on Thursday, ... to discuss its financial results and operating activities open to ...
Cached Medicine Technology:Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users 2Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users 3Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users 4Volcano Corporation Schedules Third Quarter Conference Call, Webcast 2
(Date:8/27/2015)... ... August 27, 2015 , ... The Naderi Center is proud to announce that ... noninvasive procedure to improve submental fat. The first and only Food and Drug ... Dr. Kulak is the only Board Certified surgeon in the D.C., Maryland, Virginia ...
(Date:8/27/2015)... ... August 27, 2015 , ... Healthpointe is proud to welcome Dr. Ted ... Los Angeles. Licensed to practice Chinese Needle Therapy since 1983, Dr. Priebe specializes in ... Dr. Priebe also practices in Healthpointe’s La Mirada clinic and Garden Grove clinic. ...
(Date:8/27/2015)... ... August 27, 2015 , ... In addition to its existing Doctor of ... third doctoral program at its main campus in Reading: Doctor of Nursing Practice. , ... to prepare advanced practice nurses for the highest level of clinical nursing practice. ...
(Date:8/27/2015)... ... August 27, 2015 , ... For the first ... machine with the Nutri Ninja® Auto-iQ Pro Complete and Nutri Ninja Auto-iQ Compact ... that takes drink customization to a whole new level. This line of Nutri ...
(Date:8/27/2015)... ... August 27, 2015 , ... Susan Harris and the team at ... due to pre- and post-menopause, chemotherapy, and child birth. , The MonaLisa Touch ... energy to the vaginal tissue, revitalizing cells so they make more collagen, an essential ...
Breaking Medicine News(10 mins):Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 2Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 3Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 4Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 2Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 3
... Survivors , Breast cancer survivors, particularly older ... non-cancer causes than from breast cancer. , ... longer, and many are dying of causes unrelated ... with the National Cancer Institute of Canada Clinical ...
... responsive to treatment than those with HPV-negative tumors , , ... cancer patients whose tumors test positive for human papillomavirus ... treatment than those who test negative, a new study ... to be responsible for most cervical cancers, has recently ...
... Commitment to Healthy Eating, Active Living and Safety ... ... the fourth,quarter of 2007, Kaiser Permanente approved 778 community benefit grants,totaling ... improve the health of the communities that it,serves. Funds were pledged ...
... Memorial,HealthCare, corporate parent of Northwestern Memorial Hospital, appointed,at ... to the Northwestern,Memorial Foundation,s Boards of Directors., ... as president of the Friends of Prentice,board of ... Hospital,s,Campaign Steering Committee. Gordon is chairman of Boyden ...
... and 100 mcg/hr) Not Affected, RARITAN, N.J., ... said today that all lots of 25,microgram/hour (mcg/hr) ... in the United States and all 25 mcg/hr ... States are being voluntarily,recalled as a precaution from ...
... Help Pediatric Group Improve Claims Processing, ... Appointment Scheduling and Patient Statements, ... completed an agreement with Huntsville Pediatric Associates,to provide ... helps improve appointment scheduling, medical,billing, electronic claims submission, ...
Cached Medicine News:Health News:Other highlights in the Feb. 12 JNCI 2Health News:Other highlights in the Feb. 12 JNCI 3Health News:Other highlights in the Feb. 12 JNCI 4Health News:Kaiser Permanente Approves $29 Million in Community Benefit Grants 2Health News:Kaiser Permanente Approves $29 Million in Community Benefit Grants 3Health News:Northwestern Memorial HealthCare and Northwestern Memorial Foundation Elect New Members to Board of Directors 2Health News:PriCara(TM) Recalls 25 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches 2Health News:Huntsville Pediatric Associates Selects DST Health Solutions' Practice Management Solution for Billing, Accounts Receivable 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: